Efficacy and safety of aerosol inhalation of polycolistin B in patients with severe pneumonia combined with mechanical ventilation
- VernacularTitle:多黏菌素B雾化吸入在机械通气重症肺炎患者中的有效性和安全性
- Author:
Yilei YANG
1
;
Hu ZHANG
1
;
Jia CAO
2
;
Qiaoyan YI
1
;
Xin HUANG
1
;
Yan LI
1
;
Rui YANG
1
Author Information
1. Dept. of Clinical Pharmacy，the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital，Shandong Engineering and Technology Research Center for Pediatric Drug Development，Shandong Medicine and Health Key Laboratory of Clinical Pharmacy，Jinan 250014，China
2. Center for Big Data Research in Health and Medicine，the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital，Jinan 250014，China
- Publication Type:Journal Article
- Keywords:
polycolistin B;
aerosol inhalation;
severe pneumonia;
mechanical ventilation;
efficacy;
safety
- From:
China Pharmacy
2023;34(19):2385-2390
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the efficacy and safety of aerosol inhalation of polycolistin B in the treatment of severe pneumonia combined with mechanical ventilation， and to provide a reference of real-world data for clinical drug therapy. METHODS A retrospective cohort study was conducted to analyze the clinical data of 87 patients with severe pneumonia combined with mechanical ventilation at the First Affiliated Hospital of Shandong First Medical University from January 2021 to February 2023. According to route of administration， all patients were divided into combined group （24 cases， receiving aerosol YXH2021ZX013） inhibition of polycolistin B combined with intravenous dripping） and routine group （63 cases， intravenous dripping of polycolistin B alone）. The differences in efficacy （mortality，clinical response rate and bacterial clearance rate）and safety （elevated serum creatinine， bronchospasm and skin pigmentation） were compared between two groups； the influential factors of primary outcome index as mortality were analyzed through univariate analysis and multivariate Logistic regression analysis. RESULTS In terms of efficacy， there were no statistical differences in mortality（37.50% vs. 41.27%， P＝0.749）， clinical response rate （54.17% vs. 55.56%， P＝0.907） and bacterial clearance rate （45.83% vs. 44.44%， P＝0.907） between the two groups. In terms of safety， the incidence of bronchospasm in the combined group was significantly higher than that of the routine group （12.50% vs. 0， P＝0.028）， but the differences in incidence of elevated serum creatinine and skin pigmentation between two groups were not statistically significant （P＞0.05）. Univariate analysis showed that the moralities were higher in the case of infected with Acinetobacter baumannii， Klebsiella pneumoniae and combined use of quinolones （P＜0.05）； multivariate Logistic regression analysis showed that infection with A. baumannii （OR＝3.36， P＝0.014） and combined use of quinolones （OR＝3.54， P＝0.013） were independently associated with mortality （P＜0.05）. CONCLUSIONS For severe pneumonia patients with mechanical ventilation， intravenous dripping of polycolistin B combined with aerosol inhalation does not show superior efficacy compared with intravenous dipping of polycolistin B alone， but significantly increases the incidence of bronchospasm. Infection with A. baumannii and combined use of quinolones are independent risk factors for the increase of mortality.
